Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
The Chinese e-commerce giant led by Jack Ma saw its shares pop 36 pct at the open. Staggering growth and margins proved irresistible to global investors. The company’s cloudy governance, frenetic dealmaking and corporate structure could yet prove a trap.
The Oracle founder is stepping down as CEO, but his 25 pct stake in the software giant – and dual role as chairman and chief technology officer – ensure he’s far from relinquishing control. Splitting his old job between two executives could, however, lead to a bumpy transition.
Acquisitive U.S. drugmaker Auxilium’s attempt to buy its way into a Canadian tax jurisdiction may be thwarted by M&A machine Endo International’s hostile $2.2 bln offer for Auxilium. When serial dealmakers start going after each other, it signals a dearth of suitable targets.
- Valeant gets one last shot to woo Allergan owners
- Merger Monday deal enthusiasm in rude health
- Microsoft's harbors still mined with Ballmer bombs
- Apple cooks up recipe to empty pockets and wallets
- Google finally learns from healthcare hiccups
- Square swipes a hollow-looking $6 bln valuation
- Snapchat's valuation soars on tech-land pixie dust